CN110123659B - Anti-hair loss composition and application thereof in preparation of anti-hair loss washing and protecting product - Google Patents
Anti-hair loss composition and application thereof in preparation of anti-hair loss washing and protecting product Download PDFInfo
- Publication number
- CN110123659B CN110123659B CN201910457539.2A CN201910457539A CN110123659B CN 110123659 B CN110123659 B CN 110123659B CN 201910457539 A CN201910457539 A CN 201910457539A CN 110123659 B CN110123659 B CN 110123659B
- Authority
- CN
- China
- Prior art keywords
- hair
- parts
- hair loss
- composition
- alopecia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 230000003656 anti-hair-loss Effects 0.000 title claims abstract description 53
- 238000005406 washing Methods 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title description 11
- 201000004384 Alopecia Diseases 0.000 claims abstract description 83
- 231100000360 alopecia Toxicity 0.000 claims abstract description 44
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 44
- 241000219745 Lupinus Species 0.000 claims abstract description 28
- 229930010555 Inosine Natural products 0.000 claims abstract description 27
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims abstract description 27
- 229960003786 inosine Drugs 0.000 claims abstract description 27
- 239000000047 product Substances 0.000 claims abstract description 24
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 claims abstract description 22
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960001948 caffeine Drugs 0.000 claims abstract description 22
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 22
- 108010009736 Protein Hydrolysates Proteins 0.000 claims abstract description 12
- 239000003531 protein hydrolysate Substances 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 210000004209 hair Anatomy 0.000 claims description 46
- 230000003405 preventing effect Effects 0.000 claims description 27
- 229920001661 Chitosan Polymers 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 16
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 15
- 229960003104 ornithine Drugs 0.000 claims description 15
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 11
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 11
- 229930064664 L-arginine Natural products 0.000 claims description 10
- 235000014852 L-arginine Nutrition 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003755 preservative agent Substances 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- -1 ethoxylated methyl glucoside stearate Chemical class 0.000 claims description 6
- 239000002453 shampoo Substances 0.000 claims description 6
- 229920002907 Guar gum Polymers 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 235000010417 guar gum Nutrition 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 125000005456 glyceride group Chemical group 0.000 claims description 4
- 239000003906 humectant Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940057950 sodium laureth sulfate Drugs 0.000 claims description 4
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 230000003750 conditioning effect Effects 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 2
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 claims description 2
- 229920000289 Polyquaternium Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229940073499 decyl glucoside Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229940031575 hydroxyethyl urea Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108700004121 sarkosyl Proteins 0.000 claims description 2
- 238000007493 shaping process Methods 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 229940079776 sodium cocoyl isethionate Drugs 0.000 claims description 2
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 claims description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 2
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 claims description 2
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 29
- 230000003779 hair growth Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 210000000442 hair follicle cell Anatomy 0.000 description 33
- 230000003676 hair loss Effects 0.000 description 31
- 208000024963 hair loss Diseases 0.000 description 28
- 239000000686 essence Substances 0.000 description 24
- 210000004761 scalp Anatomy 0.000 description 16
- 210000003780 hair follicle Anatomy 0.000 description 15
- 239000004475 Arginine Substances 0.000 description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
- 235000009697 arginine Nutrition 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- 230000003658 preventing hair loss Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000003128 head Anatomy 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 210000001061 forehead Anatomy 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- 241001648835 Polygonum cuspidatum Species 0.000 description 4
- 235000018167 Reynoutria japonica Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003660 hair regeneration Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 239000000498 cooling water Substances 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009583 hair follicle growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HVFAVOFILADWEZ-UHFFFAOYSA-M sodium;2-[2-(dodecanoylamino)ethyl-(2-hydroxyethyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCC(=O)NCCN(CCO)CC([O-])=O HVFAVOFILADWEZ-UHFFFAOYSA-M 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- OYINQIKIQCNQOX-UHFFFAOYSA-M 2-hydroxybutyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCC(O)C[N+](C)(C)C OYINQIKIQCNQOX-UHFFFAOYSA-M 0.000 description 1
- VFKZECOCJCGZQK-UHFFFAOYSA-M 3-hydroxypropyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCO VFKZECOCJCGZQK-UHFFFAOYSA-M 0.000 description 1
- 101800000068 Antioxidant peptide Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920000875 Dissolving pulp Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000311 effect on hepatitis Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000003721 exogen phase Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000001705 insufficient nutrition Nutrition 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940086539 peg-7 glyceryl cocoate Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 229930182852 proteinogenic amino acid Natural products 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000008364 tissue synthesis Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Abstract
The invention discloses an anti-hair loss composition and application thereof in preparing anti-hair loss washing and protecting products. The anti-hair loss composition comprises inosine, lupin hydrolyzed protein and caffeine; the weight ratio of inosine to lupin protein hydrolysate to caffeine is as follows: 1: 1-20: 1-5. The composition combines inosine, lupin protein hydrolysate and caffeine, has a remarkable alopecia stopping effect, and also has the effect of promoting hair growth.
Description
Technical Field
The invention discloses an anti-hair loss composition, belongs to the technical field of scalp care, and particularly relates to an anti-hair loss composition and application thereof.
Background
Survey data shows that the number of people with alopecia in China is as high as 1.6 hundred million. In men, every 4 people have alopecia, and with the action of external factors such as aggravation of environmental pollution, irregular diet, high working pressure and the like, the people suffering from alopecia have increasingly obvious aging, and the public health and beauty awareness is increasingly strong, so that the problem of alopecia is more and more emphasized.
Alopecia can be classified into normal alopecia and pathologic alopecia according to the difference of the cause. Normal alopecia refers to hair loss in catagen or telogen, and normal people have 70-100 hair loss per day, which is caused by metabolism of hair follicle cells of scalp and belongs to normal metabolism of human body; pathological alopecia refers to the loss of normal hair follicle cells due to hair nutrition deficiency caused by degeneration or entering the resting stage. Pathological alopecia often causes baldness, alopecia areata and the like.
Aiming at the increasing of the population suffering from pathological alopecia, a plurality of types of anti-alopecia products appear on the market. The products can be roughly divided into two types, one type of products is based on the traditional Chinese medicine theory, compound herbal extracts are adopted, and the effects such as nourishing or oil control and the like are correspondingly generated according to different formula raw materials so as to achieve the aim of preventing alopecia, but the analysis of the feedback condition after the use of consumers shows that the effect of most products is not obvious; the other kind of products are hair care products added with western medicines, mainly uses sildenafil, minoxidil and the like as active ingredients, and the products have obvious hair loss prevention and hair growth promotion effects in the early stage of use, but have obvious side effects (sexual dysfunction, low blood pressure and the like) after long-term use, and the result is unreliable.
Related studies have shown that alopecia is mainly caused by insufficient nutrition supply to hair due to degenerative atrophy of hair follicle cells in the scalp, and thus to effectively solve the problem of alopecia, it is essential to provide sufficient nutrition to hair follicle cells; meanwhile, the hair loss can be effectively prevented by matching with a proper hair follicle growth factor, but the hair follicle entering the dormancy stage is promoted to grow again, and new hair grows out, so that the problem of hair loss is completely solved. At present, in the existing technologies or products, the factors inhibiting the normal metabolism of hair follicles are eliminated through oil control so as to delay the shedding of hairs, or the blood flow of the hair follicles is increased ("blood circulation activation") so as to promote the supply of nutrition to the hair follicles, and the problems of hair loss and hair regeneration cannot be fundamentally solved.
Disclosure of Invention
The other hair face composition also stimulates the hair follicle cells in the resting period with fallen hair to activate the function of the hair follicle, so that the hair follicle cells grow new hair again, and the hair growth effect is achieved, thereby fundamentally solving the problems of hair loss and hair regeneration.
A composition for preventing alopecia comprises inosine, lupin hydrolyzed protein, and caffeine.
Preferably, the anti-hair loss composition comprises inosine, lupin hydrolyzed protein and caffeine in a mass ratio of: 1: 1-20: 1-5.
Preferably, the anti-hair loss composition has the mass ratio of inosine to lupin hydrolyzed protein to caffeine of 1: 2: 1. 1: 3: 1 or 1: 3: 2.
preferably, the anti-hair loss composition further comprises: l-arginine, ornithine, small molecular chitosan, and rhizoma Polygoni Cuspidati extract; the mass ratio of the L-arginine, the ornithine, the micromolecular chitosan and the giant knotweed extract is as follows: 1: 0.4: 0.5: 0.4.
preferably, the anti-hair loss composition comprises, by weight, 1-10 parts of inosine, 1-20 parts of lupin hydrolyzed protein, 1-5 parts of caffeine, 1-10 parts of L-arginine, 1-4 parts of ornithine, 1-5 parts of small molecular chitosan and 1-4 parts of giant knotweed rhizome extract.
Preferably, the alopecia prevention composition consists of the following components in parts by weight:
1-5 parts of inosine, 10-20 parts of lupin protein hydrolysate, 2-5 parts of caffeine, 1-5 parts of L-arginine, 1-2 parts of ornithine, 2-4 parts of micromolecular chitosan and 1-2 parts of giant knotweed extract.
Preferably, the small molecular chitosan is oligomeric chitosan with the polymerization degree of 2-20 and the molecular weight of less than or equal to 3.5 kDa.
The anti-hair loss composition is prepared by mixing the components.
Preferably, the anti-hair loss composition is used for preparing an anti-hair loss wash care product, and the anti-hair loss wash care product is prepared from 8-30% of the anti-hair loss composition; and 70-92% of additive; the dosage form of the anti-hair loss washing and caring product is selected from hair conditioner, hairdressing gel, shampoo, hair caring essence, hair caring mousse or hair beautifying and shaping product.
Preferably, the anti-hair loss composition is used for preparing an anti-hair loss wash care product, and the additive comprises:
1-5% of humectant, 0.01-3% of emulsifier, 0.01-0.5% of pH regulator, 0.01-30% of surfactant, 0.05-3% of preservative, 0.01-2% of stabilizer, 0.01-3% of excipient, 0.01-4% of conditioner and the balance of diluent.
Preferably, the anti-hair loss composition is used for preparing an anti-hair loss washing and protecting product, and the diluent is selected from one or a mixture of two of deionized water and ethanol;
the humectant is selected from one or more of hyaluronic acid (sodium), glycerol, propylene glycol, 1, 3-butanediol, hydroxyethyl urea, allantoin, sodium PCA and decyl glucoside;
the emulsifier is selected from one or more of ethoxylated methyl glucoside stearate, polyoxyethylene sorbitan monostearate (Tween), fatty glyceride, sorbitan mono fatty ester, and fatty acid citric glyceride;
the pH regulator is selected from one or more of hydrochloric acid, sulfuric acid, citric acid, lactic acid, potassium hydroxide and sodium hydroxide;
the surfactant is selected from one or more of sodium laureth sulfate, sodium methyl cocoyl taurate, sodium cocoyl isethionate, sodium cocoyl amphoacetate and sodium lauroyl sarcosinate;
the stabilizer is one or more selected from carbomer, cellulose, guar gum and xanthan gum;
the excipient is selected from one or more of ethylene glycol distearate, ethylene glycol stearate and styrene/acrylic acid (ester) copolymer;
the conditioning agent is selected from one or more of cationic guar gum, polyquaternium and silicone grease.
The invention has the following advantages and beneficial technical effects:
the invention provides an anti-hair loss composition, which comprises inosine, lupin hydrolyzed protein and caffeine, and has simple formula components. The combination of inosine, lupin hydrolyzed protein and caffeine has obvious effect of preventing alopecia, and the trial of volunteers proves that after the lupin hydrolyzed protein and caffeine are continuously used for 10 weeks, the alopecia number of testers is obviously reduced, and the alopecia preventing effect is obvious; meanwhile, the composition also has a remarkable hair growth effect, and mainly stimulates the resting-period hair follicle cells which have fallen off, so that the function of hair follicles is activated, new hair grows out from the hair follicle cells, and the effect of hair growth is achieved.
The anti-hair loss composition provided by the invention further comprises: l-arginine, ornithine, small molecular chitosan, and rhizoma Polygoni Cuspidati extract; the seven raw materials are matched for use, so that the effects of effective treatment and scientific nursing on hair follicle cells of the scalp are achieved, and the effect of the product is remarkably improved.
Detailed Description
The invention is further illustrated by the following specific examples, which are intended to be purely exemplary of a more detailed description and are not intended to limit the invention in any way.
The invention discloses an anti-hair loss composition and application thereof. The anti-hair loss composition comprises inosine, lupin protein hydrolysate (Lupine protein hydrolysate) and caffeine. Inosine, lupin hydrolyzed protein and caffeine are used in combination, so that the hair growth promoting composition has a remarkable hair loss stopping effect, and has the effect of promoting hair growth.
Inosine, also called inosine or inosine, is a nucleoside compound formed by binding inosine to ribose. Inosine is a component of ATP, coenzyme A, ribonucleic acid and deoxyribonucleic acid in the organism, participates in substance metabolism and energy metabolism of the organism, can improve the ATP level of the organism, can be converted into various nucleotides, and participates in protein synthesis, and after entering blood, exogenous inosine can enter cells through cell membranes to activate coenzyme A and pyruvate oxidase, so that the cells in a low ATP state continue to be metabolized smoothly; for the symptom of hair loss caused by degeneration and atrophy of hair follicle cells in scalp, inosine is supplemented properly, an ATP generation system of the hair follicle cells can be activated, the hair follicle cells are promoted to grow again, and the hair can grow out of hair papilla again, so that the alopecia can be effectively solved.
Lupinus micropranthus Guss is commonly called Lupinus glauca, the leaf base generates clumps, the palm-shaped compound leaves are supported by long stems to be similar to a feather fan, and therefore the name Lupinus is obtained, and the Lupinus micropranthus Guss is a perennial herb of Lupinus. Relevant researches show that lupin protein hydrolysate has antioxidant effect, and its antioxidant activity is related to the amino acid composition of polypeptide and its hydrogen and electron donating capacity. The hair follicle cells in the scalp are subjected to various oxidation pressures to generate a large amount of free radicals, the free radicals existing in the hair follicle cells can destroy various normal physiological processes of the cells, particularly the free radicals attack on a cell membrane system to cause the function loss of a cell membrane system, so that the cells are subjected to apoptosis, and therefore the appropriate intake of the antioxidant peptide can reduce the level of the free radicals in the body, delay the apoptosis of the hair follicle cells and further reduce the shedding of hairs.
Research shows that about 70% of alopecia population belongs to seborrheic alopecia (androgenetic alopecia), namely, Dihydrotestosterone (DHT) is generated by testosterone in vivo through the action of 5 a-reductase, hair follicle cells are extremely sensitive to the DHT, and the excessive DHT can stimulate the cells to generate various cytokines (such as TGF-beta 2) to cause the degeneration, premature senility and atrophy of the hair follicle cells, so that the nutrient supply of hair roots is reduced, and finally, the hair is shed. It has been shown that caffeine can help treat androgenic alopecia, thereby counteracting the negative effects of dihydrotestosterone on hair growth inhibition, and the mechanism of action is mainly due to inhibition of phosphodiesterase activity, thereby causing an increase in cyclic adenosine monophosphate (cAMP) in messenger compounds, thereby promoting hair follicle growth and prolonging the hair growth cycle.
Arginine (argine), also known as proteinogenic amino acid, is an amino acid compound. Studies have shown that arginine plays a physiological role in vivo in the major form of L-arginine; the main function of arginine in its physiological functions is to participate in protein synthesis, and the two most important of arginine are:
1) promote wound healing, and arginine can promote collagen tissue synthesis, so that the wound can be repaired. An increase in arginase activity is observed in wound exudate, which also indicates an increased arginine requirement in the vicinity of the wound; arginine promotes microcirculation around the wound, thereby promoting the wound to heal early.
2) Arginine can improve the immune function of an organism, and the conditioning effect of arginine is mainly shown in the aspects of up-regulation of immunosuppression, down-regulation of overhigh inflammatory reaction and maintenance of the immune balance of the organism. The hair follicle cells of the scalp are damaged by the external environment and are easy to cause apoptosis, so that the hair rooted in the hair follicle cells falls off, the arginine is supplemented to the damaged hair follicle cells, the healing of the damaged hair follicle cells can be effectively accelerated, and the effect of stabilizing the hair is achieved.
Ornithine is an essential intermediate metabolite in human metabolism, a non-protein amino acid. L-ornithine is one of basic amino acids, plays a very important role in the final metabolic cycle of human nitrogen, can convert amino acid generated by human protein metabolism and ammonia generated by amino acid into urea for detoxification, promotes the final metabolism of nitrogen, and promotes the urea cycle; after the ornithine enters the hair follicle cells with active metabolism, the ornithine can promote the conversion of ammonia generated by metabolism in the cells, detoxicate the cells and ensure the normal metabolism of the hair follicle cells.
The chitosan is a product of chitosan after being deacetylated by a chemical method, is the only basic polysaccharide existing in the nature, and has good biocompatibility; research shows that the chitosan with small molecular weight has the effects of bacteriostasis and sterilization; the temperature and humidity environment of the scalp is very suitable for the growth and propagation of microorganisms such as fungi, bacteria and the like on the surface layer of the scalp, and metabolites of harmful microorganisms in the growth process can stimulate scalp cells to cause itching of the head and dandruff increase, so that the scalp and hair follicle cells are damaged, and therefore the micromolecular chitosan acts on the scalp, can effectively inhibit and even kill the harmful microorganisms on the surface layer of the scalp, and achieves the effects of relieving the itching of the head and reducing the dandruff.
Polygonum cuspidatum (Polygonum cuspidatum), a perennial coarse herb of Polygonaceae, has the effects of clearing heat and promoting diuresis, relieving cough, reducing phlegm, promoting blood circulation and relaxing bowels, and has the treatment effect on hepatitis, arthritis, pneumonia, blood fat and other diseases. Modern pharmacological research shows that resveratrol in the polygonum cuspidatum extract has multiple effects of resisting oxidation, resisting inflammation and the like, and the polygonum cuspidatum extract acts on hair follicle cells of scalp, so that active free radicals in the hair follicle cells are removed, the oxidation pressure of the cells is relieved, the healing of damaged hair follicle cells is accelerated, the metabolism of the hair follicle cells is normally carried out, sufficient nutrition is provided for the growth of hair, and the hair is black and bright.
The components are all commercial products. The components are scientifically and reasonably matched, and respectively have comprehensive effects in multiple aspects of energy demand of hair follicle cell growth metabolism, oxidation pressure relief, hormone regulation, cell metabolism detoxification, inflammation repair, scalp microecology adjustment and the like, compared with a single component (or combination in other forms), the hair follicle stimulating agent has more remarkable and comprehensive effects, can effectively provide nutrition and energy for hair follicle cells in a shedding stage, improves the activity of the hair follicle cells, delays the atrophy of hair papilla, prevents the hair from shedding, stimulates the hair follicle cells in a resting stage with hair shedding, activates the function of the hair follicle, enables the hair follicle cells to grow new hair again, and further plays a role in hair growth, thereby fundamentally solving the problems of hair loss and hair regeneration.
The following are examples of the preparation of the alopecia preventing composition.
Example 1 (preparation of anti-alopecia composition)
An anti-hair loss composition is prepared from the following raw material components:
mixing inosine 1Kg, lupin protein hydrolysate 10Kg and caffeine 4Kg simply.
Example 2 preparation of alopecia preventing composition
An anti-hair loss composition is prepared from the following raw material components:
mixing inosine 1Kg, lupin protein hydrolysate 15Kg and caffeine 3Kg simply.
Example 3 preparation of alopecia preventing composition
An anti-hair loss composition is prepared from the following raw material components:
mixing inosine 1Kg, lupin protein hydrolysate 15Kg, caffeine 3Kg, L-arginine 2Kg, ornithine 1Kg, small molecular chitosan 2.5Kg, and giant knotweed rhizome extract 2Kg simply.
Example 4 preparation of alopecia preventing composition
An anti-hair loss composition is prepared from the following raw material components:
mixing inosine 1Kg, lupin hydrolyzed protein 13Kg, caffeine 4Kg, L-arginine 3Kg, ornithine 1.5Kg, small molecular chitosan 3Kg, and giant knotweed rhizome extract 1.5Kg simply.
The following are examples of the application of the alopecia preventing composition of examples 1 to 4, respectively.
Example 5 (shampoo containing anti-alopecia composition)
A preparation method of an anti-hair loss shampoo comprises the following steps:
1) stirring and heating a proper amount of deionized water to 80 ℃, adding sodium laureth sulfate, sodium lauroamphoacetate, cocamidopropyl betaine, cocamide MEA, ethylene glycol distearate and PEG-7 glyceryl cocoate, and stirring for 30min at a constant temperature to obtain a phase A;
2) adding guar gum hydroxypropyl trimethyl ammonium chloride into a proper amount of deionized water, and uniformly stirring to obtain a phase B;
3) adding the phase B into the phase A, stirring for 15min, homogenizing for 3min, introducing cooling water, cooling to 45 ℃, sequentially adding the anti-hair loss composition, the preservative, EDTA-2Na, citric acid, sodium chloride, essence and the rest deionized water described in the embodiment 1, and stirring for more than 30min to obtain the anti-hair loss shampoo.
In the hair loss preventing shampoo of the embodiment, the deionized water, sodium laureth sulfate, sodium lauroamphoacetate, cocamidopropyl betaine, cocamide MEA, ethylene glycol distearate, PEG-7 glycerol cocoate, guar hydroxypropyltrimonium chloride, the hair loss preventing composition of embodiment 1, the preservative, EDTA-2Na, citric acid, sodium chloride and the essence are in the following mass percentages: 70.2: 13.5: 4.0: 5.6: 1: 1.5: 0.3: 0.5: 0.1: 2: 0.5:0.1, 0.1: 0.5: 0.2.
example 6 Hair conditioner containing alopecia preventing composition
A preparation method of the hair loss prevention hair conditioner comprises the following steps:
1) heating a proper amount of deionized water to 80 ℃, adding hexadecanol/octadecanol, stearyl trimethyl ammonium chloride and EDTA-2Na, and stirring for 20min under heat preservation until the materials are completely dissolved;
2) and cooling the materials to 50 ℃ by introducing cooling water, sequentially adding the anti-hair loss composition, polydimethylsiloxane, preservative, essence and citric acid in the embodiment 2, continuously stirring for 30min, homogenizing for 3min, and continuously cooling to room temperature to obtain the anti-hair loss hair conditioner.
In the hair loss preventing hair conditioner of this embodiment, the deionized water, cetostearyl alcohol, stearyltrimethyl ammonium chloride, the hair loss preventing composition of embodiment 2, polydimethylsiloxane, the preservative, the essence, and the citric acid are, in mass percent: 89.6: 5: 1.5: 1: 2: 0.2: 0.5: 0.2.
example 7 (essence containing anti-alopecia composition)
A preparation method of the hair loss preventing essence comprises the following steps:
1) dissolving cellulose in deionized water at room temperature to obtain phase A;
2) adding the anti-hair loss composition, EDTA-2Na, preservative and essence in the example 3 into the phase A in sequence, and stirring uniformly to obtain the anti-hair loss essence;
in the hair loss preventing essence of this embodiment, the deionized water, the cellulose, the hair loss preventing composition described in embodiment 3, the EDTA-2Na, the preservative and the essence are, by mass: 95.9: 0.1: 3: 0.1, 0.5: 0.5.
comparative example 1
A composition, comprising: 5kg of L-arginine, 2kg of ornithine, 2.5kg of micromolecular chitosan and 1.2kg of giant knotweed extract.
The giant knotweed extracts of the above examples 4 to 7 and comparative example 1 are commercially available giant knotweed extracts, and the raw material form may be powder or liquid.
The small molecular chitosan in the above examples 4 to 7 and comparative example 1 is oligomeric chitosan with polymerization degree of 2 to 20 and molecular weight less than or equal to 3.5 kDa.
Test example for Effect verification
To verify the efficacy of the anti-hair loss composition disclosed in the present invention, the anti-hair loss compositions prepared in examples 1, 2, 3, and 4, and the composition prepared in comparative example 1 were prepared into anti-hair loss essence as follows:
the preparation method of the hair loss preventing essence comprises the following steps: mixing water, cellulose, EDTA-2Na, essence, preservative, composition or anti-alopecia composition according to the weight ratio of 96.9:0.5: 0.1: 1:0.5: 1, and uniformly stirring to obtain the hair loss preventing essence.
The hair loss prevention essences containing the hair loss prevention compositions of examples 1, 2, 3 and 4 were numbered 1 to 4, respectively, and the hair loss prevention essence containing the composition of comparative example 1 was numbered 5.
1. Effective hair follicle density and anti-hair loss condition detection
1.1 test setup:
the test groups are set to 6 groups, which are respectively numbered as 1-6 (wherein the number 6 is a blank group), and each group comprises 40 testers (including 20 males and 20 females) and the age is 25-55 years old, wherein the hair loss grades of the males of the 40 testers selected in each group are II-IV type, and the hair loss grades of the females are I type or II type.
Classification of male hair loss grade:
male alopecia generally starts from both sides of the forehead, gradually extends towards the top of the head, recedes towards the hairline of the forehead, or starts from the top of the head. Alopecia continues with the front hair line receding from the sides and the forehead becoming higher, forming what is commonly referred to as "high forehead". The hair gradually becomes thin and delicate, and the new hair becomes thinner and thinner, and is soft and powerless. Bald areas have smooth skin and fine vellus hairs are visible. It is usually accompanied by desquamation, except for slight itching, there are no other subjective symptoms.
Type I: normal or substantially normal hairstyle:
type II: the frontotemporal hairline moves backwards in a triangle, and the distance between the frontotemporal hairline and the coronal line connected with the two auditory canals can reach 2 CM;
type III: the two temporal corners recede beyond the anterior 2CM of the coronal line, and the tops are sparse;
type IV: the two temples and hairlines recede significantly, with the midforehead receding, but with intermediate density bands of hair spaced:
and V type: the frontal temporal and apical denuded areas are enlarged, during which the hair band is narrow and sparse;
type VI: horseshoe alopecia, increased lateral and posterior baldness;
type VII: in severe forms, hair loss occurs around the ear and around the occiput, except horseshoe hair loss.
Classifying female alopecia grades:
in general, female alopecia is caused by diffuse loss of hair at the top of the head, so that the top of the head is gradually thin but not completely removed, and the progress is slow.
Grade 1 (mild): the hair in the front of the coronal region becomes thin, the hairstyle needs to be changed to cover, and the forehead hairline is complete; the second part of clinical experiments researches the traditional Chinese medicine syndrome differentiation and typing of androgen-derived alopecia and the analysis of hair electron microscope experimental observation;
grade 2 (medium): the hair in the front of the coronal region becomes thinner more obviously, the range of the alopecia region is enlarged, and the change of the hair style is difficult to mask;
grade 3 (heavy): the top part is completely bald or bared, but the forehead hairline is still intact
1.2 methods of use:
the test groups numbered 1-5, the members used the hair loss preventing essence once in the morning and evening each day, each time taking 3mL of the hair loss preventing essence, applying the essence to the scalp of the hair loss part, and massaging for 5-10 min; blank group, using clear water, other same as test group; during the test, all testers did not use other anti-hair loss products except the anti-hair loss essence for the test.
1.3 effective hair follicle density detection results:
at the head alopecia part of the tester, a detection area with the area of 3cm x 3cm is selected, a hair follicle hair analyzer is adopted to shoot the detection areas of the tester at 0 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks and 10 weeks, and the result is shown in table 1.
TABLE 1 Hair follicle Density
As can be seen from table 1, the effective hair follicle density of the test person was significantly increased at week 2 after the hair loss prevention essence containing the hair loss prevention compositions of examples 1, 2, 3 and 4 was used, and then the effective hair follicle density was increased with the increase of the use time, thereby proving that the hair loss prevention composition disclosed by the present invention can effectively increase the number of effective hair follicles, and further proving that it has the effect of effectively growing hair.
1.4 alopecia-relieving effect
Collecting the number of hair loss when the tester combs, wherein the number of hair loss of the tester is collected at 0 week and 10 week after the hair loss prevention essence is used, and the method for collecting each time specifically comprises the following steps: the hair was combed on a double layer of gauze laid 1 m square, and the hair attached to the gauze was collected and counted, and the results are shown in table 2.
TABLE 2 number of comb drops
As can be seen from table 2, the number of hairs lost by the test persons 10 weeks after the use of the anti-hair loss essences containing the anti-hair loss compositions of examples 1, 2, 3 and 4 was significantly reduced as compared to that before the use (week 0), demonstrating that the anti-hair loss composition disclosed in the present invention is effective in preventing hair loss.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention in any way, so that any simple modification, equivalent change and modification made to the above embodiment according to the technical spirit of the present invention are within the scope of the technical solution of the present invention.
Claims (9)
1. An anti-hair loss composition characterized by:
the anti-hair loss composition comprises the following components in parts by weight:
1-10 parts of inosine, 1-20 parts of lupin protein hydrolysate, 1-5 parts of caffeine, 1-10 parts of L-arginine, 1-4 parts of ornithine, 1-5 parts of micromolecular chitosan and 1-4 parts of giant knotweed extract;
the weight ratio of inosine, lupin protein hydrolysate and caffeine is as follows: 1: 1-20: 1-5.
2. The alopecia preventing composition as in claim 1, wherein: the mass ratio of inosine to lupin hydrolyzed protein to caffeine is 1: 2: 1 or 1: 3: 1 or 1: 3: 2.
3. the alopecia prevention composition as in claim 1, wherein: the mass ratio of the L-arginine, the ornithine, the micromolecular chitosan and the giant knotweed extract is as follows: 1: 0.4: 0.5: 0.4.
4. the alopecia preventing composition as in claim 1, wherein: the anti-hair loss composition comprises the following components in parts by weight:
1-5 parts of inosine, 10-20 parts of lupin protein hydrolysate, 2-5 parts of caffeine, 1-5 parts of L-arginine, 1-2 parts of ornithine, 2-4 parts of micromolecular chitosan and 1-2 parts of giant knotweed extract.
5. The alopecia preventing composition as in claim 1, wherein: the micromolecular chitosan is oligochitosan with the polymerization degree of 2-20 and the molecular weight of less than or equal to 3.5 kDa.
6. The alopecia preventing composition as set forth in any one of claims 1 to 5, wherein: is prepared by mixing the components.
7. Use of the alopecia preventing composition as set forth in any one of claims 1 to 5 for preparing an alopecia preventing wash care product, characterized in that:
the anti-hair loss washing and protecting product is composed of 8-30% of an anti-hair loss composition; and 70-92% of additive;
the dosage form of the anti-hair loss washing and caring product is selected from a hairdressing gel, a shampoo, a hair caring essence, a hair caring mousse or a hair beautifying and shaping product.
8. Use according to claim 7, characterized in that: the additive comprises:
1-5% of humectant, 0.01-3% of emulsifier, 0.01-0.5% of pH regulator, 0.01-30% of surfactant, 0.05-3% of preservative, 0.01-2% of stabilizer, 0.01-3% of excipient, 0.01-4% of conditioner and the balance of diluent.
9. Use according to claim 8, characterized in that:
the diluent is selected from one or a mixture of two of deionized water and ethanol;
the humectant is selected from one or more of hyaluronic acid, glycerol, propylene glycol, 1, 3-butanediol, hydroxyethyl urea, allantoin, sodium PCA and decyl glucoside;
the emulsifier is selected from one or more of ethoxylated methyl glucoside stearate, polyoxyethylene sorbitan monostearate, fatty glyceride, sorbitan monofatty ester and fatty acid citric glyceride;
the pH regulator is selected from one or more of hydrochloric acid, sulfuric acid, citric acid, lactic acid, potassium hydroxide and sodium hydroxide;
the surfactant is selected from one or more of sodium laureth sulfate, sodium methyl cocoyl taurate, sodium cocoyl isethionate, sodium cocoyl amphoacetate and sodium lauroyl sarcosinate;
the stabilizer is one or more selected from carbomer, cellulose, guar gum and xanthan gum;
the excipient is selected from one or more of ethylene glycol distearate, ethylene glycol stearate and styrene/acrylic acid (ester) copolymer;
the conditioning agent is selected from one or more of cationic guar gum, polyquaternium and silicone grease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910457539.2A CN110123659B (en) | 2019-05-29 | 2019-05-29 | Anti-hair loss composition and application thereof in preparation of anti-hair loss washing and protecting product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910457539.2A CN110123659B (en) | 2019-05-29 | 2019-05-29 | Anti-hair loss composition and application thereof in preparation of anti-hair loss washing and protecting product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110123659A CN110123659A (en) | 2019-08-16 |
| CN110123659B true CN110123659B (en) | 2022-08-30 |
Family
ID=67582703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910457539.2A Active CN110123659B (en) | 2019-05-29 | 2019-05-29 | Anti-hair loss composition and application thereof in preparation of anti-hair loss washing and protecting product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110123659B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110693743B (en) * | 2019-10-28 | 2022-04-26 | 上海新高姿化妆品有限公司 | Hair loss preventing and hair nourishing composition, shampoo and preparation method |
| CN110882173B (en) * | 2019-12-05 | 2022-06-17 | 西北农林科技大学 | Formula of external daily chemical for preventing and treating alopecia by targeting hair follicle stem cells |
| CN113398019B (en) * | 2021-05-24 | 2022-12-09 | 上海曜爱生物科技有限公司 | Nano microemulsion system composition with anti-hair loss and hair growth functions, preparation method and application |
| CN113332201A (en) * | 2021-06-08 | 2021-09-03 | 钟娟 | Anti-hair loss shampoo and preparation method thereof |
| CN114533586A (en) * | 2021-11-23 | 2022-05-27 | 广州市科能化妆品科研有限公司 | Dandruff-removing itching-relieving shampoo composition, and preparation method and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3210669A1 (en) * | 1982-03-23 | 1983-09-29 | Hrvoje Dr. Zagreb Krnjević | Pharmaceutical composition for the treatment of disorders of the skin and mucous membranes and of nail growth |
| FR2797184A1 (en) * | 1999-08-02 | 2001-02-09 | Silab Sa | Product active against hair loss obtained by aqueous extraction of white lupin seeds |
| FR2876903A1 (en) * | 2004-10-25 | 2006-04-28 | Silab Sa | Use of an active ingredient in a cosmetic composition, to fight against alopecia e.g. by restoring the hormonal balance of capillary fibers by inhibition of 5alpha-reductase activity |
| CN103445971A (en) * | 2012-05-31 | 2013-12-18 | 祥茂生活科技股份有限公司 | Composition and method for promoting hair growth |
| CN103655257A (en) * | 2013-05-14 | 2014-03-26 | 广东太阳神集团有限公司 | Chinese medicine hair nourishing shampoo and preparation method thereof |
| CN107157804A (en) * | 2017-07-19 | 2017-09-15 | 广东德丝肤生物科技有限公司 | A kind of nutrition scalp hair follicles hair tonic elite and preparation method thereof |
| CN108324610A (en) * | 2018-03-20 | 2018-07-27 | 珀莱雅化妆品股份有限公司 | A kind of preparation method of hair growth composition and its PIC water-in-oil nano-emulsions |
-
2019
- 2019-05-29 CN CN201910457539.2A patent/CN110123659B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3210669A1 (en) * | 1982-03-23 | 1983-09-29 | Hrvoje Dr. Zagreb Krnjević | Pharmaceutical composition for the treatment of disorders of the skin and mucous membranes and of nail growth |
| FR2797184A1 (en) * | 1999-08-02 | 2001-02-09 | Silab Sa | Product active against hair loss obtained by aqueous extraction of white lupin seeds |
| FR2876903A1 (en) * | 2004-10-25 | 2006-04-28 | Silab Sa | Use of an active ingredient in a cosmetic composition, to fight against alopecia e.g. by restoring the hormonal balance of capillary fibers by inhibition of 5alpha-reductase activity |
| CN103445971A (en) * | 2012-05-31 | 2013-12-18 | 祥茂生活科技股份有限公司 | Composition and method for promoting hair growth |
| CN103655257A (en) * | 2013-05-14 | 2014-03-26 | 广东太阳神集团有限公司 | Chinese medicine hair nourishing shampoo and preparation method thereof |
| CN107157804A (en) * | 2017-07-19 | 2017-09-15 | 广东德丝肤生物科技有限公司 | A kind of nutrition scalp hair follicles hair tonic elite and preparation method thereof |
| CN108324610A (en) * | 2018-03-20 | 2018-07-27 | 珀莱雅化妆品股份有限公司 | A kind of preparation method of hair growth composition and its PIC water-in-oil nano-emulsions |
Non-Patent Citations (3)
| Title |
|---|
| 伦敦顶尖医院测评的生发产品，看着买不吃亏;悦居英国;《搜狐，获取网址：https://www.sohu.com/a/310376289_418811?sec=》;20190426;第5-6页 * |
| 肌苷片能治疗脱发吗;王亚峰;《健客网，获取网址：https://www.jianke.com/ask/question/16791341》;20160930;第1页 * |
| 这是一篇头发护理的广告;李郁实;《微薄，获取网址：https://weibo.com/ttarticle/p/show?id=2309404130575047874581》;20170717;第3-4页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110123659A (en) | 2019-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110123659B (en) | Anti-hair loss composition and application thereof in preparation of anti-hair loss washing and protecting product | |
| CN111700843B (en) | Hair loss preventing and hair nourishing shampoo and preparation method thereof | |
| KR100839704B1 (en) | Hair restorer and hair growth promoter composition | |
| CN106727157B (en) | Hair loss prevention and hair growth promoting shampoo | |
| CN107019789B (en) | Anti-hair loss and hair-growing traditional Chinese medicine composition, preparation method and application thereof | |
| CN108938445B (en) | Anti-hair loss composition and application thereof, anti-hair loss product comprising anti-hair loss composition and preparation method | |
| CN115252649B (en) | Application of thermophilic bacteria fermentation product in preventing alopecia and/or growing hair, composition and preparation thereof | |
| CN115120547B (en) | Non-irritating hair repair composition and anti-hair-loss shampoo | |
| CN112754956A (en) | Formula and preparation method of cactus polysaccharide anti-inflammatory moisturizing mask | |
| CN112870333A (en) | Composition and preparation for improving alopecia and promoting hair growth of human, and preparation method and application thereof | |
| CN114224807B (en) | Shampoo containing Chinese honeylocust fruits and bitter almonds and preparation method thereof | |
| CN114533624A (en) | White hair blackening liquid and preparation method thereof | |
| CN105555285A (en) | Composition for promoting hair sprouting and hair growth | |
| KR100778662B1 (en) | Cleansing composition containing natural oriental plant extracts | |
| KR101830864B1 (en) | Cosmetic composition for inhibiting hair loss and enhanching hair growth | |
| CN105168046B (en) | A kind of hair growth composition containing plant extracts | |
| CN112569159A (en) | Hair loss preventing and caring composition, hair caring essence and preparation method thereof | |
| CN113633585B (en) | External hair care composition and preparation with effects of preventing alopecia, promoting hair growth and blackening hair and preparation method thereof | |
| CN113476354A (en) | Hair loss preventing and hair nourishing hair conditioner | |
| JPH03167113A (en) | Hair regenerating agent | |
| JP2001139436A (en) | Hair tonic and grower | |
| JP7161302B2 (en) | Wnt10b production promoter and scalp and hair cosmetic containing the same | |
| CN112675094A (en) | Plant extract, repairing composition, skin care product and preparation method thereof | |
| CN115887337A (en) | Hair care shampoo and preparation method thereof | |
| CN117530904A (en) | Plant composition with anti-hair loss effect and shampoo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240227 Address after: 515834 Liannan Industrial Zone, Chenghai District, Shantou City, Guangdong Province Patentee after: Guangdong Mingchen Daily Chemical Co.,Ltd. Country or region after: China Address before: 515834 Liannan Industrial Zone, Lianxia Town, Chenghai District, Shantou City, Guangdong Province Patentee before: MINGCHEN HEALTH Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |